Effect of various disease states on theophylline plasma levels and on pulmonary function in patients with chronic airway obstruction treated with a sustained release theophylline preparation.

Abstract	Theophylline plasma levels and FEV1 were measured in patients affected by chronic obstructive pulmonary disease and a concomitant disease state (congestive heart failure, chronic cor pulmonale, obesity, peptic disease, hepatic cirrhosis, chronic renal failure) and treated with a sustained release theophylline preparation. Our results indicate that, only in patients affected by congestive heart failure and chronic cor pulmonale, is there a decreased plasma clearance of the drug. Low levels of plasma theophylline were measured in obese patients probably because they received an inadequate posology.
Authors	R Dal Negro, P Turco, C Pomari, P Monici-Preti
Journal	International journal of clinical pharmacology, therapy, and toxicology (Int J Clin Pharmacol Ther Toxicol) Vol. 25 Issue 7 Pg. 401-5 (Jul 1987) ISSN: 0174-4879 [Print] Germany
PMID	3305382 (Publication Type: Clinical Trial, Journal Article)
Chemical References	Delayed-Action Preparations Theophylline
Topics	Clinical Trials as Topic Delayed-Action Preparations Digestive System Diseases (blood, complications) Heart Diseases (blood, complications) Humans Kidney Failure, Chronic (blood, complications) Kinetics Lung Diseases, Obstructive (blood, complications, drug therapy) Obesity (blood, complications) Theophylline (blood, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!